Clark D J, Grove A, Cargill R I, Lipworth B J
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, UK.
Thorax. 1996 Mar;51(3):262-6. doi: 10.1136/thx.51.3.262.
A study was performed to compare the adrenal suppression caused by inhaled fluticasone propionate and budesonide on a microgram equivalent basis, each given by metered dose inhaler to asthmatic patients.
Twelve asthmatic patients of mean age 29.9 years, with a forced expiratory volume in one second (FEV1) 92.9% predicted and forced expiratory flow 25-75% (FEF25-75) 69.5% predicted, on less than or equal to 400 micrograms/day inhaled corticosteroid, were studied in a double blind placebo controlled crossover design comparing single doses of inhaled budesonide 400, 1000, 1600, 2000 micrograms and fluticasone propionate 500, 1000, 1500, 2000 micrograms. Doses were administered at 22.00 hours by metered dose inhaler with mouth rinsing and measurements were made in the laboratory 10 hours later.
Serum cortisol levels compared with placebo (mean 325.2 nmol/l) were suppressed by fluticasone at doses of 1500 micrograms (211.6 nmol/l) and 2000 micrograms (112.3 nmol/l) and by budesonide at 2000 micrograms (243.4 nmol/l). Fluticasone propionate 2000 micrograms produced lower absolute serum cortisol levels than budesonide 2000 micrograms (95% CI for difference 42.9 to 219.2). The dose ratio (geometric mean) for the relative potency was 2.89 fold (95% CI 1.19 to 7.07). In terms of percentage suppression versus placebo, fluticasone propionate also produced greater effects (means and 95% CI for difference): budesonide 1600 micrograms (16.0) versus fluticasone propionate 1500 micrograms (40.9) (95% CI -0.6 to 50.6), budesonide 2000 micrograms (26.0) versus fluticasone 2000 micrograms (65.2) (95% CI 10.5 to 67.8). Individual serum cortisol levels at the two highest doses showed 15 of 24 patients below the normal limit of the reference range (150 nmol/l) for fluticasone and five of 24 for budesonide. Fluticasone propionate also caused greater ACTH suppression than budesonide (as % versus placebo): budesonide 1600 micrograms (12.0) versus fluticasone propionate 1500 micrograms (31.9) (95% CI 7.6 to 32.1), budesonide 2000 micrograms (13.5) versus fluticasone propionate 2000 micrograms (44.4) (95% CI 13.2 to 48.7). For overnight 10 hour urinary cortisol (nmol/10 hours) there was a difference between the lowest doses of the two drugs: budesonide 400 micrograms (37.2) versus fluticasone propionate 500 micrograms (19.9) (95% CI 6.9 to 27.8).
Like budesonide the systemic bioactivity of fluticasone propionate is mainly due to lung vascular absorption. Fluticasone propionate exhibited at least twofold greater adrenal suppression than budesonide on a microgram equivalent basis in asthmatic patients.
开展了一项研究,以比较在微克等效剂量基础上,通过定量气雾剂给予哮喘患者吸入丙酸氟替卡松和布地奈德所引起的肾上腺抑制作用。
12例平均年龄29.9岁的哮喘患者,一秒用力呼气量(FEV1)为预计值的92.9%,25%-75%用力呼气流量(FEF25-75)为预计值的69.5%,吸入糖皮质激素剂量小于或等于400微克/天,采用双盲安慰剂对照交叉设计,比较单剂量吸入400、1000、1600、2000微克布地奈德和500、1000、1500、2000微克丙酸氟替卡松的效果。剂量于22:00通过定量气雾剂给药,同时进行漱口,10小时后在实验室进行测量。
与安慰剂(平均325.2纳摩尔/升)相比,1500微克和2000微克剂量的丙酸氟替卡松以及2000微克剂量的布地奈德均使血清皮质醇水平受到抑制。2000微克丙酸氟替卡松产生的绝对血清皮质醇水平低于2000微克布地奈德(差异的95%置信区间为42.9至219.2)。相对效价的剂量比(几何均值)为2.89倍(95%置信区间为1.19至7.07)。就相对于安慰剂的抑制百分比而言,丙酸氟替卡松也产生了更大的效果(均值及差异的95%置信区间):1600微克布地奈德(16.0)与1500微克丙酸氟替卡松(40.9)(95%置信区间为-0.6至50.6),2000微克布地奈德(26.0)与2000微克氟替卡松(65.2)(95%置信区间为10.5至67.8)。在两种最高剂量下,24例患者中有15例的丙酸氟替卡松个体血清皮质醇水平低于参考范围的正常下限(150纳摩尔/升),布地奈德则为24例中有5例。丙酸氟替卡松对促肾上腺皮质激素的抑制作用也大于布地奈德(相对于安慰剂的百分比):1600微克布地奈德(12.0)与1500微克丙酸氟替卡松(31.9)(95%置信区间为7.6至32.1),2000微克布地奈德(13.5)与2000微克丙酸氟替卡松(44.4)(95%置信区间为13.2至48.7)。对于过夜10小时尿皮质醇(纳摩尔/10小时),两种药物的最低剂量之间存在差异:400微克布地奈德(37.2)与500微克丙酸氟替卡松(19.9)(95%置信区间为6.9至27.8)。
与布地奈德一样,丙酸氟替卡松全身生物活性主要归因于肺血管吸收。在微克等效剂量基础上,丙酸氟替卡松对哮喘患者肾上腺的抑制作用比布地奈德至少强两倍。